Asset Details
Do you wish to reserve the book?
Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis
Do you wish to request the book?
Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis
2025
Overview
This study delved into the role of the PI3K/AKT signaling pathway and cuproptosis in steroid-induced osteonecrosis of the femoral head (SIONFH), assessing the therapeutic potential of the PI3K agonist 740Y-P. We analyzed femoral head specimens from SIONFH patients using DIA proteomics, identifying differentially expressed proteins linked to cuproptosis. In vitro, MC3T3-E1 cells treated with dexamethasone (DEX) exhibited hallmarks of cuproptosis, including downregulation of DLAT, PDHB, SLC25A3, and FDX1, increased copper ions, and reduced osteogenic potential, as shown by decreased ALP activity and RUNX2/BMP2 expression. The PI3K/AKT pathway’s modulation of FDX1 was key to cuproptosis regulation; activating it with 740Y-P restored FDX1 levels and partially recovered osteogenic capacity. An in vivo rat model of SIONFH treated with 740Y-P demonstrated improved bone parameters, reversed osteogenic suppression, and upregulated PI3K/AKT/FDX1 expression, validating the pathway’s role in cuproptosis and the agonist’s therapeutic potential for treating SIONFH and glucocorticoid-associated bone disorders.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
1-Phosphatidylinositol 3-kinase
/ 631/337
/ 692/420
/ 740Y-P
/ Agonists
/ Animals
/ Copper
/ Dexamethasone - adverse effects
/ Female
/ Femur
/ Femur Head Necrosis - chemically induced
/ Femur Head Necrosis - metabolism
/ Femur Head Necrosis - pathology
/ Femur Head Necrosis - prevention & control
/ Genes
/ Glucocorticoids - adverse effects
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Male
/ Mice
/ Necrosis
/ Phosphatidylinositol 3-Kinases - metabolism
/ Proteins
/ Proto-Oncogene Proteins c-akt - metabolism
/ Rats
/ Science
/ Signal Transduction - drug effects
/ Steroid-induced osteonecrosis of the femoral head
/ Steroids
